Alzheimer's Disease Research Reagents

Alzheimer’s disease (AD) is the leading cause of dementia worldwide, driven by amyloid-β plaque deposition, tau hyperphosphorylation, and neuroinflammation. The therapeutic landscape now includes anti-amyloid immunotherapies (lecanemab, donanemab) alongside BACE1 inhibitors and tau-targeting approaches — making biomarker-validated research reagents essential for preclinical target validation, companion diagnostic development, and disease mechanism studies.

Research Use Only (RUO) Not intended for diagnostic or therapeutic procedures.

Alzheimer disease pathogenesis pathway - amyloid cascade, tau hyperphosphorylation, neuroinflammation, TREM2 microglial activation, ApoE clearance

Fig. 1 Major pathogenic pathways in Alzheimer’s disease. Key research targets highlighted in orange.

abinScience provides validated antibodies, recombinant proteins, and ELISA kits for established and emerging Alzheimer’s disease research targets — including Aβ/APP, Tau/Phospho-Tau, TREM2, ApoE, and NfL. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets in Alzheimer’s Disease

Amyloid-β (Aβ42) & APP — Aβ42 peptides generated by BACE1/γ-secretase cleavage of APP aggregate into neurotoxic plaques. Anti-Aβ antibodies and recombinant APP proteins support plaque quantification by IHC, ELISA-based Aβ42/40 ratio measurement, and anti-amyloid immunotherapy mechanism-of-action studies.
→ Browse Aβ/APP antibodies & proteins

Tau (MAPT) & Phospho-Tau — Hyperphosphorylated tau (pTau181, pTau217, pTau231) detaches from microtubules and forms neurofibrillary tangles (NFTs). Anti-phospho-tau antibodies enable CSF/plasma biomarker assay development, IHC Braak staging, and tau-targeted therapeutic research.
→ Browse Tau/Phospho-Tau antibodies

TREM2 — TREM2 is a microglial receptor regulating Aβ phagocytosis and neuroinflammatory responses. TREM2 variants (R47H) are major genetic risk factors for late-onset AD. Anti-TREM2 antibodies support microglial activation profiling and soluble TREM2 measurement.
→ Browse TREM2 antibodies & proteins

ApoE (ε2/ε3/ε4) — ApoE4 is the strongest genetic risk factor for sporadic AD, impairing Aβ clearance across the blood-brain barrier. Anti-ApoE isoform-specific antibodies enable genotype-stratified biomarker studies and BBB transport research.
→ Browse ApoE antibodies & proteins

Neurofilament Light Chain (NfL) — Serum/CSF NfL is a validated biomarker for neurodegeneration severity and treatment response monitoring across AD clinical trials. Anti-NfL antibodies support ultrasensitive immunoassay (Simoa) development and longitudinal disease progression studies.

References

1. van Dyck CH, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9-21. DOI

2. Sims JR, et al. Donanemab in early symptomatic Alzheimer disease (TRAILBLAZER-ALZ 2). JAMA. 2023;330(6):512-527. DOI

3. Jack CR Jr, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535-562. DOI

4. Palmqvist S, Janelidze S, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772-781. DOI

5. Keren-Shaul H, et al. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell. 2017;169(7):1276-1290. DOI